Is Synvista Therapeutics Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Synvista Therapeutics Inc (SYNI) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Synvista Therapeutics Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Synvista Therapeutics Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Synvista Therapeutics Inc?

Muslim investors may consider investing in Synvista Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Synvista Therapeutics Inc classified as NOT COVERED?

Musaffa determines the Shariah status of Synvista Therapeutics Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Synvista Therapeutics Inc updated?

The Shariah compliance status of Synvista Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Synvista Therapeutics Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Synvista Therapeutics Inc?

You can check the latest Shariah compliance status of Synvista Therapeutics Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Synvista Therapeutics Inc. Stock Analysis SYNI

United States Health Care Nano Cap

Synvista Therapeutics, Inc. is a biotechnology company, which engages in the development of diagnostic tests and pharmaceutical drugs for the treatment of diabetes. The company is headquartered in Montvale, New Jersey and currently employs 9 full-time employees. The firm's lead drug candidate, alagebrium chloride or alagebrium, is an advanced glycation end-product crosslink breaker being developed for diastolic heart failure (DHF). Synvista is also managing a discovery and development program to produce small molecule drugs that mimic the enzyme glutathione peroxidase (GPx). One of the Company’s GPx mimetics, ALT-2074, is in Phase II clinical trials.

Financial Metrics & Statements of Synvista Therapeutics Inc (SYNI)

FAQ's for Synvista Therapeutics Inc (SYNI)

According to Musaffa’s Shariah screening methodology, Synvista Therapeutics Inc (SYNI) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.